Stock DiscoverySign in
Back to Discover

4D Molecular Therapeutics, Inc.

FDMT · Biotech · Nasdaq · As of 10 Sep 2026
61AIR SCORE
  • FundamentalsNot enough data yet
  • ValueNot enough data yet
  • News flowBalanced
  • MomentumVery strong
  • SafetyBalanced

Overall confidence 38/100 — few inputs available yet

Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on discovery, market confirmation and risk, at reduced overall confidence.

Discovery Gap: Very high (57/100) · Gap confidence 54/100Documented progress is running well ahead of market attention.

This month at a glance

AIR Score™ change: 0AIR Score™ held steady this month.
Cycle window9 Sep 2026 → 10 Sep 2026
MoversNothing moved meaningfully this month.

Evidence timeline

  1. [8-K 2.02] 4D Molecular Therapeutics, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
    Aug 13, 2026 · 8-K
  2. [8-K 8.01] 4D Molecular Therapeutics, Inc. — Other EventsSEC · SEC EDGAR
    Jul 18, 2026 · 8-K
  3. [8-K 1.01] 4D Molecular Therapeutics, Inc. — Entry into a Material Definitive AgreementSEC · SEC EDGAR
    Jun 24, 2026 · 8-K
  4. [8-K 2.03] 4D Molecular Therapeutics, Inc. — Creation of a Material Direct Financial ObligationSEC · SEC EDGAR
    Jun 24, 2026 · 8-K
  5. [8-K 2.02] 4D Molecular Therapeutics, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
    May 7, 2026 · 8-K
  6. [8-K 5.02] 4D Molecular Therapeutics, Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGAR
    Mar 25, 2026 · 8-K
  7. [8-K 2.02] 4D Molecular Therapeutics, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
    Mar 18, 2026 · 8-K
  8. [8-K 3.02] 4D Molecular Therapeutics, Inc. — Unregistered Sales of Equity SecuritiesSEC · SEC EDGAR
    Jan 22, 2026 · 8-K
  9. [8-K 5.02] 4D Molecular Therapeutics, Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGAR
    Dec 31, 2025 · 8-K
  10. [8-K 2.02] 4D Molecular Therapeutics, Inc. — Results of Operations and Financial ConditionSEC · SEC EDGAR
    Dec 31, 2025 · 8-K
  11. [8-K 8.01] 4D Molecular Therapeutics, Inc. — Other EventsSEC · SEC EDGAR
    Dec 10, 2025 · 8-K
  12. [8-K 5.02] 4D Molecular Therapeutics, Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGAR
    Nov 17, 2025 · 8-K

Ask AIR

What would change our view

A weaker balance sheet in the next filing cycle, a material regulatory setback, or attention arriving — which closes the gap by design would move the score, and the page would show which one did.

Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.